Company intelligence / Profile preview
Vesselon
- Ownership
- Private
- Development stage
- Commercial
Overview
Vesselon's preclinical data show that their co-formulation technology can enhance cellular uptake and bioavailability of drugs by multiple fold compared to traditional methods. Their oncolytic virus complex has shown efficacy at low titers across a range of tumors in preclinical models. The IL‑2 complex targets solid tumors with reduced systemic exposure. Clinical results pending initiation of human trials.
- Therapeutic areas
- OncologyRare DiseasesCardiovascularNeurologyInfectious Diseases
- Modalities
- Lipid microspheres (microbubbles)Self-assembling liposomesOncolytic viruses (encapsulated)Recombinant proteins (e.g., interleukin‑2)Monoclonal antibodiesNucleic acids
- Industry
- Biotech
Drug pipeline
3 assets2 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Vesselon.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vesselon.